Pluristem soars as Israeli Covid-19 patients improve

Yaky Yanay Photo: Einat Levron
Yaky Yanay Photo: Einat Levron

Pluristem has treated seven Covid-19 patients in Israel with its PLX cells under a compassionate use program.

Haifa-based Pluristem Therapeutics Inc. (Nasdaq:PSTI; TASE: PSTI: PSTI) announced last week that four of six Israeli Covid-19 patients treated for a week or more with its PLX stem cells were showing signs of improvement. All the patients in question were on ventilators and were suffering from acute respiratory failure and inflammatory complications associated with Covid-19. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure, indicating critical disease and poor prognosis. The rate of recovery among patients in this condition up to now has been around 50%.

A seventh patient treated with Pluristem's product has not yet completed seven day follow up. Three patients are in advanced stages of weaning from ventilators.

Pluristem's share price rose 43.17% in New York on Thursday to $6.97, giving the company a market cap of $124 million. On the Tel Aviv Stock Exchange this morning, Pluristem's share price is up nearly 65%, at NIS 23.67.  

The treatment of the seven patients was on a compassionate basis and does not constitute a clinical trial. There is no comparison with a control group of patients. Nevertheless, the outcome so far is encouraging, and Pluristem will continued to offer its treatment under the compassionate use program in Israel.

The company says that, as a next step, it plans to apply for initiation of a multinational regulated clinical trial program for the potential use of PLX cells in the treatment of patients suffering from complications associated with Covid-19. Meanwhile, it does not intend to provide further updates on the status of this program.

"We are pleased with this initial outcome of the compassionate use program, and committed to harnessing PLX cells for the benefit of patients and healthcare systems. In order to maximize PLX cells’ impact on patient recovery and to work towards making our treatment widely available, we plan to quickly move forward into a clinical development program," said Pluristem CEO and president Yaky Yanay.

"Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need. We believe that research and governmental funding may be available to Pluristem to support the use of PLX cells for patients suffering from Covid-19 and are targeting such funding," Yanay added.

Published by Globes, Israel business news - en.globes.co.il - on April 12, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Yaky Yanay Photo: Einat Levron
Yaky Yanay Photo: Einat Levron
Israeli startup gems 2022 Globes names Finout "Most Promising Startup of 2025"

Cloud cost management solutions company Finout tops the list of Israeli startups most likely to succeed named by 80 local and foreign funds.

Mobileye CEO Amnon Shashua credit: Heinz Troll European Patent Office Mobileye posts strong Q1, reaffirms guidance despite tariffs

The Israeli advanced driving assistance systems company beat analysts' expectations on revenue and met expectations on non-GAAP net profit.

Xtend drones credit: Xtend Sentrycs teams with Xtend to strengthen drone security

The aim of the all-Israeli collaboration is to create a synergy of proven capabilities in a world where drones have become a major threat.

Intel Haifa  credit: Shutterstock Intel layoffs in Israel will benefit rivals

Industry experts agree that Intel staff dismissed in Israel will have no trouble finding work at rivals like Nvidia, as happened during last year's layoffs.

Ministry of Finance Jerusalem credit: Shutterstock Treasury sees Trump's tariffs cutting Israel's GDP growth

Amid the uncertainty that still surrounds the level of tariffs that would ultimately be imposed on Israeli goods, the annual damage to growth is estimated by the Finance Ministry at less than 0.5% of GDP.

French President Emmanuel Macron at the Paris Air Show in 2023 credit: Reuters Israel to scale down Paris Air Show presence

Due to President Emmanuel Macron's antagonism, Israel is reducing its presence at the exhibition, Ministry of Defense International Defense Cooperation Directorate (SIBAT) head Yair Kulas tells "Globes."

Jerusalem court cmplex credit: Zarhy Architects Tenders issued for two huge Jerusalem construction projects

The PFI tenders for the Gan Hotzvim tech campus and the courts complex include grants of NIS 1.7 billion for the winning bidders.

Israel Innovation Authority CEO Dror Bin Innovation Authority chief: Israel top for deep tech investment

Dror Bin told the Globes TECH IL conference that deep tech is the next wave for global tech and the rate of investment in Israel is the world's highest.

Gil Shwed and Nadav Zafrir credit: Menash Cohen With new CEO Check Point beats analysts in Q1

Revenue rose 6.5% and GAAP net profit rose 5% in Nadav Zafrir's first full quarter at the helm.

Tel Aviv light rail credit: Yossi Cohen Rishon Lezion to finance Red Line light rail extension

The Rishon Lezion Municipality will pay for part of the extension by marketing land above the planned underground depot.

Intel Haifa development center credit: Shutterstock Intel to cut 20% of workforce - report

"Bloomberg" reports that new CEO Lip-Bu Tan will announce the layoffs this week.

Healthee team credit: Healthee PR AI healthcare costs management co Healthee raises $50m

Healthee’s benefits and care navigation platform empowers employees and employers to make the most of their health benefits.

Former Shufersal CEO Itzik Abercohen credit: Eyal Izhar Competition Authority summons former Shufersal CEO to hearing

According to the indictment, Shufersal and Itzik Abercohen allegedly made public statements through which he attempted to reach arrangements to raise prices.

Reco founders Ofer Klein, Gal Nakash, and Tal Shapira credit: Elegant Photographics Israeli SaaS security co Reco raises $25m

The Tel Aviv-based company has developed a comprehensive application discovery engine capable of identifying and classifying over 50,000 applications, and providing visibility into an organization’s SaaS ecosystem.

Tel Aviv Stock Exchange credit: Tali Bogdanovsky TASE outperforms global markets in 2025

Boosted by the strong results of Israel's banks, the Tel Aviv Stock Exchange has demonstrated impressive resilience to domestic and foreign upheavals.

Metro credit: Bar Lavi Can Hyundai fill Metro vacuum created by China's exclusion?

The South Korean giant is reportedly eager to enter Israel's infrastructure sector but may not have the resources to dig the Metro tunnels.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018